Mastectomy for management of breast cancer in Ibadan, Nigeria

BMC Surgery

Clement A Adebamowo²  Adeyinka F Ademola¹  Omobolaji O Ayandipo¹  Temidayo O Ogundiran¹ 

[1] Division of Oncology, Department of Surgery, University College Hospital, PMB 5116 Ibadan, Nigeria;Department of Epidemiology and Preventive Medicine, University of Maryland, Maryland, USA

关键词: Nigeria;    Mastectomy;    Breast cancer;   

Others  :  866894
DOI  :  10.1186/1471-2482-13-59

 received in 2013-05-13, accepted in 2013-12-10,  发布年份 2013

【 摘 要 】

Background

Modified radical mastectomy remains the standard therapeutic surgical operation for breast cancer in most parts of the world. This retrospective study reviews mastectomy for management of breast cancer in a surgical oncology division over a ten year period.

Methods

We reviewed the case records of consecutive breast cancer patients who underwent mastectomy at the Surgical Oncology Division, University College Hospital (UCH) Ibadan between November 1999 and October 2009.

Results

Of the 1226 newly diagnosed breast cancer patients over the study period, 431 (35.2%) patients underwent mastectomy making an average of 43 mastectomies per year. Most patients were young women, premenopausal, had invasive ductal carcinoma and underwent modified radical mastectomy as the definitive surgical treatment. Prior to mastectomy, locally advanced tumors were down staged in about half of the patients that received neo-adjuvant combination chemotherapy. Surgical complication rate was low. The most frequent operative complication was seroma collection in six percent of patients. The average hospital stay was ten days and most patients were followed up at the surgical outpatients department for about two years post-surgery.

Conclusions

There was low rate of mastectomy in this cohort which could partly be attributable to late presentation of many patients with inoperable local or metastatic tumors necessitating only palliative or terminal care. Tumor down-staging with neo-adjuvant chemotherapy enhanced surgical loco-regional tumor control in some patients. The overall morbidity and the rates of postoperative events were minimal. Long-term post-operative out-patients follow-up was not achieved as many patients were lost to follow up after two years of mastectomy.

【 授权许可】

   
2013 Ogundiran et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Kufe DW, Pollock RE, Weichselbaum RR (Eds): Holland-Frei Cancer Medicine 6. 6th edition. Hamilton, Ontario, Canada: BC Decker; 2003.
• [2]Zurrida S, Bassi F, Arnone P, et al.: The changing face of mastectomy (from mutilation to Aid to breast reconstruction). Int J Surg Oncol 2011, 2011:980158.
• [3]Adebamowo CA, Ajayi OO: Breast cancer in Nigeria. West Afr J Med 2000, 19:179-191.
• [4]El Saghir NS, Adebamowo CA, Anderson BO, et al.: Breast cancer management in low resource countries (LRCs): consensus statement from the breast health global initiative. Breast 2011, 20(Suppl 2):S3-S11.
• [5]Broadwater JR, Edwards MJ, Kuglen C, Hortobagyi GN, Ames FC, Balch CM: Mastectomy following preoperative chemotherapy. Strict operative criteria control operative morbidity. Ann Surg 1991, 213:126-129.
• [6]Grilli R, Mainini F, Penna A, et al.: Inappropriate Halsted mastectomy and patient volume in Italian hospitals. Am J Public Health 1993, 83:1762-1764.
• [7]Lee DW, Vallance S: Surgical management of breast cancer in a small peripheral New Zealand hospital. ANZ J Surg 2006, 76:1060-1063.
• [8]El-Tamer MB, Ward BM, Schifftner T, Neumayer L, Khuri S, Henderson W: Morbidity and mortality following breast cancer surgery in women: National benchmarks for standards of care. Ann Surg 2007, 245:665-671.
• [9]Anyanwu SN, Egwuonwu OA, Ihekwoaba EC: Acceptance and adherence to treatment among breast cancer patients in Eastern Nigeria. Breast 2011, 20(Suppl 2):S51-S53.
• [10]Adebamowo CA, Adekunle OO: Case-controlled study of the epidemiological risk factors for breast cancer in Nigeria. Br J Surg 1999, 86:665-668.
• [11]Clegg-Lamptey JN, Dakubo JC, Hodasi WM: Comparison of four-day and ten-day post- mastectomy passive drainage in Accra, Ghana. East Afr Med J 2007, 84:561-565.
• [12]Clegg-Lamptey J, Hodasi W: A study of breast cancer in korle bu teaching hospital: assessing the impact of health education. Ghana Med J 2007, 41:72-77.
• [13]Ibrahim NA, Oludara MA: Socio-demographic factors and reasons associated with delay in breast cancer presentation: a study in Nigerian women. Breast 2012, 21:416-418.
• [14]Anders CK, Johnson R, Litton J, Phillips M, Bleyer A: Breast cancer before age 40 years. Semin Oncol 2009, 36:237-249.
• [15]Bird PA, Hill AG, Houssami N: Poor hormone receptor expression in East African breast cancer: evidence of a biologically different disease? Ann Surg Oncol 2008, 15:1983-1988.
• [16]Adebamowo CA, Famooto A, Ogundiran TO, Aniagwu T, Nkwodimmah C, Akang EE: Immunohistochemical and molecular subtypes of breast cancer in Nigeria. Breast Cancer Res Treat 2008, 110:183-188.
• [17]Gukas ID, Jennings BA, Mandong BM, et al.: Clinicopathological features and molecular markers of breast cancer in Jos, Nigeria. West Afr J Med 2005, 24:209-213.
• [18]Ikpatt OF, Kuopio T, Ndoma-Egba R, Collan Y: Breast cancer in Nigeria and Finland: Epidemiological, clinical and histological comparison. Anticancer Res 2002, 22:3005-3012.
• [19]Bertheau P, Cazals-Hatem D, Meignin V, et al.: Variability of immunohistochemical reactivity on stored paraffin slides. J Clin Pathol 1998, 51:370-374.
• [20]Olapade-Olaopa EO, MacKay EH, Habib FK: Variability of immunohistochemical reactivity on stored paraffin slides. J Clin Pathol 1998, 51:943.
• [21]Murray E: Breast cancer clinic at Groote Schuur Hospital. In AORTIC Newsletter. South Africa: AORTIC; 2005:10-1.
• [22]Middleton LP, Chen V, Perkins GH, Pinn V, Page D: Histopathology of breast cancer among African-American women. Cancer 2003, 97:253-257.
• [23]Nichols HB, Trentham-Dietz A, Love RR, et al.: Differences in breast cancer risk factors by tumor marker subtypes among premenopausal Vietnamese and Chinese women. Cancer Epidemiol Biomarkers Prev 2005, 14:41-47.
• [24]Anyanwu SN, Nwose P, Ihekwoaba E, Mbaeri AT, Chukwuanukwu TO: Neoadjuvant chemotherapy for locally advanced premenopausal breast cancer in Nigerian women: early experience. Niger J Clin Pract 2010, 13:215-217.
• [25]Schwartz GF, Hortobagyi GN: Proceedings of the consensus conference on neoadjuvant chemotherapy in carcinoma of the breast, April 26–28, 2003, Philadelphia, Pennsylvania. Cancer 2004, 100:2512-2532.
• [26]Muss HB, Woolf S, Berry D, et al.: Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA 2005, 293:1073-1081.
• [27]Lee S, Kim SW, Kim SK, et al.: Locoregional recurrence of breast conserving surgery after preoperative chemotherapy in korean women with locally advanced breast cancer. J Breast Cancer 2011, 14:289-295.
• [28]Jatol I: Options in breast cancer local therapy: who gets what? World J Surg 2012, 36:1498-1502.
• [29]Litiere S, Werutsky G, Fentiman IS, et al.: Breast conserving therapy versus mastectomy for stage I-II breast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomised trial. Lancet Oncol 2012, 13:412-419.
• [30]Pysz M: Blood transfusions in breast cancer patients undergoing mastectomy: Possible importance of timing. J Surg Oncol 2000, 75:258-263.
• [31]Aslan S, Akinci M, Cetin B, Cakmak H, Pirhan Y, Cetin A: Postoperative changes related to intraoperative blood transfusions. Bratisl Lek Listy 2011, 112:575-578.
• [32]Leinung S, Schonfelder M, Winzer KJ, et al.: Wound infection and infection-promoting factors in breast cancer surgery – a prospective multicenter study on quality control. Zentralbl Chir 2005, 130:16-20.
• [33]Eickhoff JH, Andersen J, Laybourn C: Perioperative blood transfusion does not promote recurrence and death after mastectomy for breast cancer. The Danish breast cancer cooperative group. Br J Surg 1991, 78:1358-1361.
• [34]Akyol AM, Galloway DJ, George WD: Perioperative blood transfusion does not promote recurrence and death after mastectomy for breast cancer. Br J Surg 1992, 79:470.
• [35]Malik H, Bishop H, Winstanley J: Audit of blood transfusion in elective breast cancer surgery–do we need to group and save pre-operatively? Ann R Coll Surg Engl 2008, 90:472-473.
• [36]Ezeome ER, Adebamowo CA: Closed suction drainage versus closed simple drainage in the management of modified radical mastectomy wounds. S Afr Med J 2008, 98:712-715.
• [37]Edwards MJ, Broadwater JR, Bell JL, Ames FC, Balch CM: Economic impact of reducing hospitalization for mastectomy patients. Ann Surg 1988, 208:330-336.
• [38]Purushotham AD, McLatchie E, Young D, et al.: Randomized clinical trial of no wound drains and early discharge in the treatment of women with breast cancer. Br J Surg 2002, 89:286-292.
• [39]Tarazi R, Esselstyn CB Jr, Kuivila T, Hardesty I: Early hospital discharge following mastectomy. Cleve Clin Q 1984, 51:579-584.
• [40]Wedgwood KR, Benson EA: Non-tumour morbidity and mortality after modified radical mastectomy. Ann R Coll Surg Engl 1992, 74:314-317.
• [41]Yilmaz KB, Dogan L, Nalbant H, et al.: Comparing scalpel, electrocautery and ultrasonic dissector effects: the impact on wound complications and pro-inflammatory cytokine levels in wound fluid from mastectomy patients. J Breast Cancer 2011, 14:58-63.
• [42]Kuroi K, Shimozuma K, Taguchi T, et al.: Pathophysiology of seroma in breast cancer. Breast Cancer 2005, 12:288-293.
• [43]Anyanwu SN: Survival following treatment of primary breast cancer in eastern Nigeria. East Afr Med J 2000, 77:539-543.